Improvements in health-related quality of life and the effect of disease on productivity at Week 256. Values are mean ± SD or n (%).
| Variables | Placebo + MTX | Golimumab 100 mg + Placebo | Golimumab + MTX | Total | ||
|---|---|---|---|---|---|---|
| 50 mg | 100 mg | Combined | ||||
| SF-36 PCS score | ||||||
| Improvement from baseline | 6.6 ± 11.9 | 9.2 ± 9.8 | 9.5 ± 9.6 | 9.0 ± 9.7 | 9.3 ± 9.6 | 8.5 ± 10.4 |
| Patients with score ≥ 50 | 19 (21.6) | 25 (27.5) | 19 (25.7) | 13 (22.0) | 32 (24.1) | 76 (24.4) |
| SF-36 MCS score | ||||||
| Improvement from baseline | 4.7 ± 11.6 | 2.7 ± 11.1 | 4.1 ± 9.4 | 4.4 ± 11.8 | 4.3 ± 10.5 | 3.9 ± 11.0 |
| Patients with score ≥ 50 | 45 (51.1) | 43 (47.3) | 38 (51.4) | 26 (44.1) | 64 (48.1) | 152 (48.7) |
| Improvement from baseline in the effect of disease on productivity | 2.2 ± 3.2 | 2.7 ± 2.9 | 2.8 ± 2.6 | 2.6 ± 2.9 | 2.7 ± 2.8 | 2.6 ± 2.9 |
MTX: methotrexate; SF-36: Medical Outcomes Study Short Form-36; PCS: physical component summary; MCS: mental component summary.